Market Place
Sourcing Support
Norwich Pharmaceuticals Generic Rifaximin Receives Tentative Approval in US
20 Jun 2024 //
FDA
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
20 Jun 2024 //
ACCESSWIRE
Salix runs Xifaxan TV spot with `Scandal` actor Bellamy Young
10 May 2024 //
FIERCE PHARMA
Salix Announces Bellamy Young As Xifaxan Spokesperson
09 May 2024 //
ACCESSWIRE
Court Blocks Norwich`s ANDA Approval Until 2029
11 Apr 2024 //
ACCESSWIRE
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
05 Apr 2024 //
ACCESSWIRE
Bausch notches win in Xifaxan case against Alvogen
03 Nov 2023 //
FIERCE PHARMA
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL`s ™
19 Jun 2023 //
ACCESSWIRE
Norwich`s Generic Rifaximin Receives Approval in the U.S.
02 Jun 2023 //
FDA
U.S. District Court Upholds Final Judgment for XIFAXAN® 550 mg
17 May 2023 //
PRESS RELEASE
Salix Will Present Rifaximin Data at AASLD`s The Liver Meeting(R) 2022
04 Nov 2022 //
ACCESSWIRE
Salix Will Present XIFAXAN(R, TRULANCE and RELISTOR Data at Scientific Meeting
24 Oct 2022 //
ACCESSWIRE
Bausch Health Responds to Norwich Tentative FDA Approval for a 200 mg Rifaximin
09 Sep 2022 //
PRNEWSWIRE
Norwich`s Generic Rifaximin Receives Approval in the U.S.
02 Sep 2022 //
FDA
Bausch Health`s Xifaxan is `prior art,` does not infringe Curia patents
19 Aug 2022 //
ENDPTS
Alvogen Announces Ruling on Patents Related to the Company’s Proposed Generic
11 Aug 2022 //
BUSINESSWIRE
Salix to Share New Data from XIFAXAN Clinical Research at EASL 2022
20 Jun 2022 //
PRNEWSWIRE
Bausch Health`s Rifaximin Receives FDA Orphan Designation For SCD
29 Oct 2020 //
BIOSPACE
Studying effect of glyceryl palmitostearate amount, manufacturing
24 Aug 2020 //
PHARMAEXCIPIENTS
Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® IPL
06 May 2020 //
PRNEWSWIRE
Salix To Highlight New Data Across Its Portfolio Products At Digestive Disease
30 Apr 2020 //
PRNEWSWIRE
Bausch Health Announces Favorable Topline Results Formulation of Rifaximin
31 Mar 2020 //
PR NEWSWIRE
Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market
13 Sep 2019 //
BIOSPACE
Bausch shed Valeant`s name but still leans on price hikes
16 Aug 2019 //
FIERCE PHARMA
Cosmo to give Bausch Health a run for its money with FDA nod for Xifaxan rival
21 Nov 2018 //
FIERCE PHARMA
FDA approves new drug to treat travelers’ diarrhea
17 Nov 2018 //
FDA
Bausch Health aims top-seller Xifaxan at new diseases to pump up growth
10 Aug 2018 //
FIERCE PHARMA
Valeant partner Cosmo turns wannabe IBS-D rival, and it could do some sales damage: analyst
29 Jan 2018 //
FIERCE PHARMA
Friulchem Reports on Patent Ruling for Rifaximin
10 Jan 2018 //
DCATVCI
Copying Valeant`s Xifaxan just got `a lot easier,` thanks to new FDA guidance
21 Mar 2017 //
FIERCE PHARMA
Valeant touts Salix salesforce scale-up amid rumors of mass rep exit
27 Feb 2017 //
FIERCE PHARMA
How much can a new EVP help Valeant`s badly battered derm unit?
14 Dec 2016 //
FIERCE PHARMA
Valeant looks to revive Xifaxan with primary care sales effort. Will it work?
02 Dec 2016 //
FIERCE PHARMA
Valeant Said to Keep Salix After Takeda Deal Falls Apart
01 Dec 2016 //
BLOOMBERG
Valeant Announces Initiation Of A Primary Care Sales For Xifaxan & Relistor
29 Nov 2016 //
PR NEWSWIRE
Allergan teams with star paratriathlete in yet another effort to boost Viberzi
23 Nov 2016 //
FIERCE PHARMA
Blam! Takeda’s superhero adventures are back with four new characters
07 Nov 2016 //
FIERCE PHARMA
Valeant Said to Be in Talks for Sale of Salix to Takeda
02 Nov 2016 //
BLOOMBERG
The rifaximin-α for hepatic encephalopathy can reduce costs to health systems
31 Oct 2016 //
PR NEWS WIRE
Allergan snags tech partner for IBS-D platform
25 Oct 2016 //
FIERCE PHARMA
Allergan continues Viberzi push with online IBS-D awareness tool
26 May 2016 //
FIERCE PHARMA
Exclusive: Valeant calls in investment banks to weigh options - sources
14 Apr 2016 //
REUTERS
Vexing IBS-D spokescharacter `Irritabelle` headlines Allergan`s Viberzi ad push
11 Apr 2016 //
FIERCE PHARMA MARKETING
AbbVie`s Humira, Pfizer`s Lyrica kick off 2016 with hefty TV ad spend
09 Mar 2016 //
FIERCE PHARMA MARKETING
Pharma`s DTC ad spending soars past $5B in 2015
07 Mar 2016 //
FIERCE PHARMA MARKETING
Head of Valeant`s embattled dermatology unit exits in management shakeup
04 Mar 2016 //
FIERCE PHARMA
Rhodes Pharma’s Aptensio Challenged in latest USFDA Para IV Certification List
29 Feb 2016 //
TWOFOUR INSIGHT
Allergan Announces Receipt Of FDA Acceptable For Filing Letter For XIFAXAN® ANDA
29 Feb 2016 //
PR NEWSWIRE
Valeant, AstraZeneca played the Super Bowl ad game, but did they win?
08 Feb 2016 //
FIERCE PHARMA MARKETING
BMS` Opdivo repeats, new flu ads join list of top pharma ad spending for Nov
14 Dec 2015 //
FIERCE PHARMA MARKETING
Valeant`s wobbly pink `Gut Guy` for Xifaxan is getting noticed
14 Dec 2015 //
FIERCE PHARMA MARKETING
Two new analyzes demonstrate the cost-effectiveness of rifaximin 550mg-?
19 Nov 2015 //
PR NEWS WIRE
AbbVie`s Humira repeats, joined by BMS` Opdivo in leading TV spending
18 Nov 2015 //
FIERCE PHARMA MARKETING
Scandal-plagued Valeant CEO focuses on damage control
10 Nov 2015 //
FIERCE PHARMA
Allergan`s H2 looks lighter without generics, but 10% growth on tap for 2016
30 Sep 2015 //
FIERCE PHARMA
Forecast-beating Valeant ups 2015 guidance with fast-growing Xifaxan in mind
23 Jul 2015 //
FIERCE PHARMA
5 Drugs That Could Be Summer Blockbusters
27 May 2015 //
INVESTERS.COM
Lupin Launches Zaxine® in Canada
20 Apr 2015 //
LUPIN
NICE Rules On Celgene`s Imnovid, BI`s Jardiance, Norgine`s Targaxan
26 Mar 2015 //
PHARMATIMES
